U.S. Stock Market Midday Update: Apollomics up 161.34% in six months, attracting attention due to active capital despite no news support

U.S. Stock Market Midday Update Apollomics, up 8.01%, with a six-month increase of 161.34%, has no significant news recently. Trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Q32 Bio, up 79.32%, with a trading volume of $783 million, has a six-month increase of 107.78%, and no significant news recently. Trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Precision Science down 0.02%. Based on recent news, On November 30, Motley Fool recommended Precision Science, considering it a quality stock. This recommendation may have attracted some investor attention but did not significantly drive up the stock price. On November 29, Halper Sadeh LLP encouraged Precision Science shareholders to contact law firms to discuss their legal rights. This news may have raised concerns among some investors, leading to a slight decline in the stock price. The overall market is quite volatile, and investor sentiment is cautious. AbbVie down 1.46%. Based on recent key news: On December 1, AbbVie reported third-quarter net income of $15.776 billion, a year-on-year increase of 9.1%. Sales growth for immunology and neuroscience product lines was 11.9% and 20.2%, respectively, but sales in the oncology department fell by 0.3%, with global sales of Imbruvica down 14.8%. Nevertheless, the company raised its full-year revenue forecast to $16.9 billion and plans to increase quarterly cash dividends by 5.5% in 2026. This news has a positive impact on the stock price. On November 29, market analysts rated AbbVie as "moderate buy," but it was not included in the top recommended stocks list. Analysts believe there are five other stocks with greater investment value, which may put pressure on AbbVie's stock price. On December 1, AbbVie's earnings per share information at the Lang & Schwarz exchange showed the market status as closed, with no trading activity observed, which may lead to investor concerns about liquidity. The pharmaceutical industry has shown stable performance recently, with clear capital inflows. Stocks with High Market Capitalization in the Industry Amgen down 2.39%. Based on recent key news: On December 1, the FDA is about to make a decision on Amgen's Uplizna drug expansion application, and market concerns about the regulatory outcome have led to a decline in the stock price. The FDA's decision may affect Amgen's market share in the treatment of myasthenia gravis, increasing uncertainty for investors. On November 30, analyst reports indicated that Amgen's stock is rated as hold and was not included in the recommended buy list. Analysts believe there are five other stocks with greater investment value, which undermines market confidence in Amgen On November 29th, although Amgen's DCF analysis indicates that it is undervalued, its price-to-earnings ratio is higher than the industry average, leading to a divergence in investor valuation. Analysts believe its valuation is reasonable, but market reactions are mixed. The biotechnology industry faces regulatory risks and capital outflows